4.8 Article

Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery

期刊

ACS NANO
卷 14, 期 9, 页码 11238-11253

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.0c03109

关键词

nanomedicine; immuno-oncology; nanoparticle; drug delivery; layer-by-layer; cytokine

资金

  1. Koch Institute Core Grant from the NCI [P30-CA14051]
  2. U.S. Department of Defense Congressionally Directed Medical Research Programs [W81XWH13-1-0151]
  3. Koch Institute for Integrative Cancer Research at MIT [1-R01CA235375-01A1]
  4. Dana-Farber/Harvard Cancer Center, NIH [1-R01CA235375-01A1]
  5. Marble Center for Cancer Nanomedicine
  6. Cancer Center Support (core) Grant from the National Cancer Institute [P30CA14051]
  7. Koch Institute's Marble Center for Cancer Nanomedicine Fellowship
  8. Sloan UCEM Fellowship
  9. Siebel Scholars Fellowship
  10. National Science Foundation [GFRP 1122374]
  11. MIT Undergraduate Research Opportunity Office
  12. Frost Environmental Science/Studies Fund [EN34770]
  13. Ronald E. McNair PostBaccalaureate Achievement Program [GR26419]
  14. NIH interdepartmental biotechnology training program [5T32GM008334-30]
  15. Koch Institute from the National Cancer Institute [P30-CA14051]
  16. MIT MRSEC Shared Experimental Facilities Grant from the National Science Foundation [DMR-0819762]

向作者/读者索取更多资源

Although cytokine therapy is an attractive strategy to build a more robust immune response in tumors, cytokines have faced clinical failures due to toxicity. In particular, interleukin-12 has shown great clinical promise but was limited in translation because of systemic toxicity. In this study, we demonstrate an enhanced ability to reduce toxicity without affecting the efficacy of IL-12 therapy. We engineer the material properties of a NP to meet the enhanced demands for optimal cytokine delivery by using the layer-by-layer (LbL) approach. Importantly, using LbL, we demonstrate cell-level trafficking of NPs to preferentially localize to the cell's outer surface and act as a drug depot, which is required for optimal payload activity on neighboring cytokine membrane receptors. LbL-NPs showed efficacy against a tumor challenge in both colorectal and ovarian tumors at doses that were not tolerated when administered carrier-free.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据